Proxsys Rx Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Proxsys Rx's estimated annual revenue is currently $20.7M per year.(i)
  • Proxsys Rx's estimated revenue per employee is $201,000

Employee Data

  • Proxsys Rx has 103 Employees.(i)
  • Proxsys Rx grew their employee count by 24% last year.

Proxsys Rx's People

NameTitleEmail/Phone
1
Chief PharmacistReveal Email/Phone
2
Chief PharmacistReveal Email/Phone
3
VP Human ResourcesReveal Email/Phone
4
VP, IntegrationsReveal Email/Phone
5
VP GrowthReveal Email/Phone
6
VP AccountingReveal Email/Phone
7
Director Information Services and TechnologyReveal Email/Phone
8
Chief Strategy OfficerReveal Email/Phone
9
Director, Facilities & ImplementationReveal Email/Phone
10
Chief Operating OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$18.9M944%N/AN/A
#2
$10.3M51-28%N/AN/A
#3
$44.8M2237%N/AN/A
#4
$16.5M82-1%N/AN/A
#5
$26.7M1334%N/AN/A
#6
$42M209-3%N/AN/A
#7
$1.4M148%N/AN/A
#8
$66.3M330-3%N/AN/A
#9
$13.9M691%N/AN/A
#10
$32.2M160-10%N/AN/A
Add Company

What Is Proxsys Rx?

Proxsys Rx is a healthcare solutions company that vertically integrates outpatient pharmacy into the continuum of care for health systems and their affiliated contracting agents. Proxsys Rx finances and operates local outpatient pharmacy operations, providing health care systems with long-term cost savings by reducing readmissions, improving HCAHPS scores, and improving other key health system strategic indicators that impact reimbursements and margins and accelerate Meaningful Use compliance. Key Benefits for Hospitals and Medical Centers : Bedside Rx delivery Reduced Readmissions Decreased employee medical expense Improved patient satisfaction scores Enhanced 340 B savings While 10 percent of healthcare costs are spent on prescriptions drugs, their ability to control the health status of patients and the cost of care is enormous. Emerging healthcare compensation initiatives (e.g. Shared Savings, Gain Sharing, etc.) are rapidly replacing traditional fee-for-service models. Hospitals and health systems are one of several categories that will be held accountable for the quality, cost, and care for specific groups of patients. An integrated outpatient pharmacy initiative can be a key contributor to guaranteeing health systems success by ensuring appropriateness of medication use, reducing medication-related adverse events, preventing hospital readmissions, helping patients manage chronic conditions and much more.

keywords:N/A

N/A

Total Funding

103

Number of Employees

$20.7M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Proxsys Rx News

2022-04-20 - Armed robber leaves restaurant with cash, food

Proxsys Rx, partnering with John C. Stennis Memorial Hospital, is opening a community pharmacy in DeKalb by mid-December.

2022-04-19 - BUCHANAN/The French center holds

Proxsys Rx, partnering with John C. Stennis Memorial Hospital, is opening a community pharmacy in DeKalb by mid-December.

2022-04-19 - LOWRY/Let Disney be an example

Proxsys Rx, partnering with John C. Stennis Memorial Hospital, is opening a community pharmacy in DeKalb by mid-December.

2021-03-19 - ProxsysRX and Talon collaborate to offer outpatient follow-up solution

ProxsysRX and Talon collaborate to offer outpatient follow-up solution ProxsysRx is forming a strategic partnership with Talon Health Data Solutions to reduce unnecessary hospital readmissions and improve patient satisfaction scores (HCAHPS) through their comprehensive omnichannel communication ...

2020-12-15 - ProxsysRx Receives Equity Investment

ProxsysRx, a Birmingham, Ala.-based healthcare solutions company, received a growth equity investment from Atlanta-based Fulcrum Equity Partners with participation from members of the management team. The amount of the deal was not disclosed. Fulcrum Partners Tom Greer and Jeff Muir lead the fu ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.3M10311%N/A
#2
$29.9M103-6%N/A
#3
$33.1M103-59%N/A
#4
$35M1043%N/A
#5
$12.5M1043%N/A